Cyclo Therapeutics (NASDAQ:CYTH) Receives New Coverage from Analysts at HC Wainwright

HC Wainwright started coverage on shares of Cyclo Therapeutics (NASDAQ:CYTH) in a report released on Wednesday, Benzinga reports. The brokerage issued a buy rating and a $3.00 price objective on the stock.

Separately, Ascendiant Capital Markets started coverage on shares of Cyclo Therapeutics in a report on Monday, April 22nd. They issued a buy rating and a $2.60 target price for the company.

Cyclo Therapeutics Stock Down 0.7 %

CYTH opened at $1.45 on Wednesday. Cyclo Therapeutics has a twelve month low of $0.89 and a twelve month high of $2.57. The company has a 50-day simple moving average of $1.47 and a 200 day simple moving average of $1.47. The stock has a market capitalization of $41.64 million, a price-to-earnings ratio of -1.11 and a beta of -0.15.

Cyclo Therapeutics (NASDAQ:CYTH) last posted its quarterly earnings data on Monday, March 18th. The company reported ($0.23) earnings per share for the quarter. Cyclo Therapeutics had a negative return on equity of 4,506.97% and a negative net margin of 1,864.03%. The firm had revenue of $0.31 million for the quarter.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Cyclo Therapeutics stock. Founders Fund V Management LLC bought a new position in Cyclo Therapeutics, Inc. (NASDAQ:CYTH) in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 480,708 shares of the company’s stock, valued at approximately $764,000. Cyclo Therapeutics comprises 80.8% of Founders Fund V Management LLC’s portfolio, making the stock its biggest holding. Founders Fund V Management LLC owned approximately 2.11% of Cyclo Therapeutics as of its most recent SEC filing. 68.55% of the stock is currently owned by institutional investors and hedge funds.

About Cyclo Therapeutics

Cyclo Therapeutics, Inc, a clinical stage biotechnology company, engages in the development of cyclodextrin-based products for the treatment of neurodegenerative diseases. The company's lead drug candidate is Trappsol Cyclo (hydroxypropyl beta cyclodextrin), an orphan drug, which is in Phase III clinical trials for the treatment of Niemann-Pick Type C disease; and in Phase IIb clinical trials for the treatment of Alzheimer's disease.